市場調査レポート
商品コード
1069887

ヒトマイクロバイオームの世界市場:製品別 (プレバイオティクス、プロバイオティクス、食品、診断検査、薬剤)・用途別 (治療、診断)・疾患別 (感染症、代謝障害・内分泌疾患)・研究技術別 (ゲノミクス、プロテオミクス、メタボロミクス) の将来予測 (2029年まで)

Human Microbiome Market by Product(Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application(Therapeutic, Diagnostic), Disease(Infectious, Metabolic/Endocrine), Research Technology(Genomics, Proteomics, Metabolomics) - Global Forecast -2029

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 182 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=136.22円
ヒトマイクロバイオームの世界市場:製品別 (プレバイオティクス、プロバイオティクス、食品、診断検査、薬剤)・用途別 (治療、診断)・疾患別 (感染症、代謝障害・内分泌疾患)・研究技術別 (ゲノミクス、プロテオミクス、メタボロミクス) の将来予測 (2029年まで)
出版日: 2022年04月11日
発行: MarketsandMarkets
ページ情報: 英文 182 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のヒトマイクロバイオームの市場規模は、2023年の2億6,900万米ドルから、2029年までに13億7,000万米ドルに達すると予測されています。

また、2023年から2029年までのCAGRは31.1%と予想されています。市場の主な促進要因として、ヒトマイクロバイオーム療法開発への注目度の上昇や、薬剤開発の有効な標的としてのヒトマイクロバイオームの活用、疾患の早期発見・診断向けのヒトマイクロバイオームベース検査の開発などが挙げられます。

製品分野別では、薬剤分野が最大のシェアを占めています。用途別では診断分野が、技術別ではシーケンシング分野が、最も高いCAGRで成長する見通しです。地域別に見ると、北米が最大の市場となっています。

当レポートでは、世界のヒトマイクロバイオームの市場について分析し、市場の基本構造や最新情勢、主な市場促進・抑制要因、市場動向の見通し、用途別・技術別・種類別・製品別・疾患別・地域別の詳細動向、市場競争の状態、主要企業のプロファイルなどを調査しております。

目次

第1章 イントロダクション

第2章 分析方法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概略

  • イントロダクション
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
    • 課題
  • COVID-19感染拡大:ヒトマイクロバイオーム市場に与える影響
  • 規制分析
  • 特許分析

第6章 ヒトマイクロバイオーム市場:用途別

  • イントロダクション
  • 治療
  • 診断

第7章 ヒトマイクロバイオーム市場:技術別

  • イントロダクション
  • ゲノミクス
    • シーケンシング
    • その他のゲノミクス技術
  • プロテオミクス
  • メタボロミクス

第8章 ヒトマイクロバイオーム市場:種類別

  • イントロダクション
  • 微生物叢移植 (FMT)
  • ペプチド
  • LBP (Live Biotherapeutic Products)
  • その他

第9章 ヒトマイクロバイオーム市場:製品別

  • イントロダクション
  • 薬物
  • 診断検査
  • プロバイオティクス
  • プレバイオティクス
  • その他の製品

第10章 ヒトマイクロバイオーム市場:疾患別

  • イントロダクション
  • 感染症
  • 胃腸疾患
  • 内分泌疾患・代謝障害
  • がん
  • その他の疾患

第11章 ヒトマイクロバイオーム市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • 他の欧州諸国
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 他のアジア太平洋諸国
  • その他の地域 (ROE)

第12章 競合情勢

  • 概要
  • 企業のフットプリント:製品種類別ト
  • 企業のフットプリント:臨床段階別
  • 企業のフットプリント:疾患別
  • 競合シナリオ

第13章 企業プロファイル

  • 主要企業
    • ENTEROME
    • SERES THERAPEUTICS
    • 4D PHARMA PLC
    • INTERNATIONAL FLAVORS & FRAGRANCES INC.
    • OPTIBIOTIX HEALTH PLC.
    • SYNLOGIC, INC.
    • SECOND GENOME INC.
    • VEDANTA BIOSCIENCES, INC.
    • FERRING PHARMACEUTICALS
    • EVELO BIOSCIENCES, INC.
    • BIOMX
    • YSOPIA BIOSCIENCE
    • KALEIDO BIOSCIENCES, INC.
    • FLIGHTPATH BIOSCIENCES, INC.
    • FINCH THERAPEUTICS GROUP, INC.
    • QUANTBIOME, INC.(DBA OMBRE)
    • VIOME LIFE SCIENCES, INC.
    • BIOHM HEALTH
  • その他の企業
    • DAYTWO
    • ATLAS BIOMED
    • BIONE
    • LUXIA SCIENTIFIC
    • METABIOMICS
    • SUN GENOMICS

第14章 付録

目次
Product Code: BT 2711

The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029. The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth.

"By product segment, the drugs segment accounted for the largest share of human microbiome market:"

Based on product, the human microbiome market is segmented into probiotics, prebiotics, diagnostic tests, drugs, and other products. Drugs segment accounted for the largest product segment in the human microbiome market. The large share of this segment can be attributed to the increasing number of human microbiome-based drug products in clinical trials and rising funding to develop microbiome-based drugs

"By application, the diagnostics segment is expected to grow at the highest CAGR during the forecast period."

Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The diagnostics segment is expected to grow at the highest CAGR during the forecast period. Advances in life science research on a wide number of diseases, technological innovations in human genome mapping, the emergence of omics technologies, and the increasing emphasis on improving the cost-effectiveness of healthcare and patient outcomes are some of the major factors driving the growth of this segment.

"By genomic technologies, the sequencing segment is expected to grow at the highest CAGR during the forecast period."

Based on technology, the human microbiome market is further segmented into sequencing and other genomic technologies {PCR, microarray, and fluorescent in situ hybridization (FISH)}. The availability of advanced, efficient, and accurate next-generation sequencing systems at a low cost, along with the reduced cost of sequencing, has greatly boosted the adoption of the latest sequencing technologies in the human microbiome market

"North America: The largest region in the human microbiome market."

In the human microbiome market, North America is estimated to maintain its vanguard during the forecast period. Factors such as the increasing incidence of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotic products are the factors driving the North American human microbiome market.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

By Designation: Managers: 55%, Executives: 25%, and CXOs: 20%,

By Region: North America: 50%, Europe: 20%, APAC: 20%, and RoW: 10%

Prominent players in the human microbiome market include ENTEROME Bioscience (France), Seres Therapeutics. (US), 4D pharma (UK), OptiBiotix Health (UK), Synlogic (US), International flavors & Fragrances (US), Second Genome (US), Vedanta Biosciences (US), Ferring Pharmaceuticals (Switzerland), Evelo Biosciences (US), ViThera Pharmaceuticals (US), BiomX (Israel), Kaleido (US), YSOPIA Bioscience (France), FlightPath (US), Finch Therapeutics (US), Quantbiome (DBA Thyrve, Inc.) (US), Viome, Inc. (US), DayTwo (US), BIOHM (US), Atlas Biomed (UK), Bione (India), Luxia Scientific (France), Sun Genomics (US), and Metabiomics (US).

Research Coverage:

The report segments the human microbiome market based on region (Asia Pacific, Europe, North America, and RoW), product (prebiotics, probiotics, drugs, diagnostic tests, and other products), technology (Genomics, Proteomics, and Metabolomics), application (therapeutics and diagnostics), disease (hospitals & clinics, research centers and academic & government institutes, pharmaceutical & biotechnology companies, and other end users). The report also provides a comprehensive review of market drivers, opportunities, restraints, and challenges in the human microbiome market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall human microbiome market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 MARKETS COVERED FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET
    • 1.3.3 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME RESEARCH SPENDING MARKET)
    • 1.3.4 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME MARKET)
  • 1.4 CURRENCY
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY SOURCES
    • FIGURE 1 BREAKDOWN OF PRIMARIES: HUMAN MICROBIOME MARKET
  • 2.2 MARKET DATA ESTIMATION AND TRIANGULATION
    • FIGURE 2 DATA TRIANGULATION METHODOLOGY
    • 2.2.1 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 MARKET SIZE ESTIMATION APPROACH: R&D SPENDING ANALYSIS-BASED ESTIMATION (FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET)
    • FIGURE 4 HUMAN MICROBIOME RESEARCH SPENDING MARKET SIZE (USD MILLION): FINAL MARKET SIZE
    • 2.2.2 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • FIGURE 5 FINAL CAGR PROJECTIONS (2023-2029)
    • 2.2.3 POTENTIAL MARKET SIZE CALCULATION FOR HUMAN MICROBIOME MARKET
    • FIGURE 6 HUMAN MICROBIOME MARKET SIZE BASED ON EPIDEMIOLOGY APPROACH
  • 2.3 INSIGHTS FROM PRIMARIES
    • FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
  • 2.4 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

    • FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION)
    • FIGURE 9 HUMAN MICROBIOME MARKET SHARE, BY APPLICATION, 2029
    • FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 11 GEOGRAPHICAL SNAPSHOT OF HUMAN MICROBIOME MARKET

4 PREMIUM INSIGHTS

  • 4.1 HUMAN MICROBIOME: MARKET OVERVIEW
    • FIGURE 12 INCREASING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE MARKET GROWTH
  • 4.2 HUMAN MICROBIOME MARKET, BY TYPE (2023 VS. 2029)
    • FIGURE 13 FMT TO DOMINATE HUMAN MICROBIOME MARKET IN 2023
  • 4.3 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT & APPLICATION (2023)
  • 4.4 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY (2023-2029)
    • FIGURE 14 CHINA TO GROW AT THE HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 MARKET DRIVERS
      • 5.2.1.1 Rising industry-academia collaborations for microbiome research
      • 5.2.1.2 Increasing focus on human microbiome therapeutics development
      • 5.2.1.3 Human microbiome as a validated target for drug development
      • 5.2.1.4 Development of human microbiome-based tests for early disease detection & diagnosis
    • 5.2.2 MARKET RESTRAINTS
      • 5.2.2.1 Barriers in proving the causal link between dysbiosis and diseases
      • 5.2.2.2 Negative clinical data will adversely impact public perception of microbiomes
    • 5.2.3 MARKET OPPORTUNITIES
      • 5.2.3.1 Increasing collaborations between public-private organizations
    • 5.2.4 MARKET CHALLENGES
      • 5.2.4.1 Government regulations
      • 5.2.4.2 Lack of expertise and inadequate research
  • 5.3 IMPACT OF THE COVID-19 PANDEMIC ON THE HUMAN MICROBIOME MARKET
  • 5.4 REGULATORY ANALYSIS
    • 5.4.1 REGULATORY LANDSCAPE FOR HUMAN MICROBIOME-BASED DRUGS
    • 5.4.2 REGULATORY LANDSCAPE FOR HUMAN MICROBIOME-BASED FOODS
  • 5.5 PATENT ANALYSIS

6 HUMAN MICROBIOME MARKET, BY APPLICATION

  • 6.1 INTRODUCTION
    • TABLE 1 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • 6.2 THERAPEUTIC APPLICATIONS
    • 6.2.1 AVAILABILITY OF FUNDING FOR MICROBIOME-BASED THERAPEUTIC PRODUCTS DEVELOPMENT TO DRIVE MARKET GROWTH
    • TABLE 2 HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 3 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY 2023-2029 (USD MILLION)
    • TABLE 4 EUROPE: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY 2023-2029 (USD MILLION)
    • TABLE 5 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY 2023-2029 (USD MILLION)
  • 6.3 DIAGNOSTIC APPLICATIONS
    • 6.3.1 INCREASING FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET GROWTH
    • TABLE 6 HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 7 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY 2023-2029 (USD MILLION)
    • TABLE 8 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY 2023-2029 (USD MILLION)
    • TABLE 9 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY 2023-2029 (USD MILLION)

7 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 10 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)
  • 7.2 GENOMICS
    • TABLE 11 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 12 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 13 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 14 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 15 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.2.1 SEQUENCING
    • TABLE 16 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 17 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 18 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 19 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 20 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY METHOD, 2021-2029 (USD MILLION)
      • 7.2.1.1 16S rRNA Sequencing Method
        • 7.2.1.1.1 Cost-effectiveness to propel identification of bacterial strains
    • TABLE 21 16S RRNA SEQUENCING METHOD, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 22 NORTH AMERICA: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 23 EUROPE: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 24 ASIA PACIFIC: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2021-2029 (USD MILLION)
      • 7.2.1.2 Whole-Genome Sequencing (WGS)Method
        • 7.2.1.2.1 WGS to generate accurate reference genomes for microbial identification
    • TABLE 25 WGS METHOD, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 26 NORTH AMERICA: WGS METHOD, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 27 EUROPE: WGS METHOD, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 28 ASIA PACIFIC: WGS METHOD, BY COUNTRY, 2021-2029 (USD MILLION)
      • 7.2.1.3 Other Sequencing Methods
    • TABLE 29 OTHER SEQUENCING METHODS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 30 NORTH AMERICA: OTHER SEQUENCING METHODS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 31 EUROPE: OTHER SEQUENCING METHODS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: OTHER SEQUENCING METHODS BY COUNTRY, 2021-2029 (USD MILLION)
    • 7.2.2 OTHER GENOMIC TECHNOLOGIES
    • TABLE 33 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 34 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 35 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)
  • 7.3 PROTEOMICS
    • 7.3.1 TECHNOLOGICAL ADVANCEMENTS IN PROTEOMIC TECHNOLOGIES TO DRIVE MARKET GROWTH
    • TABLE 37 PROTEOMICS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 38 NORTH AMERICA: PROTEOMICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 39 EUROPE: PROTEOMICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 40 ASIA PACIFIC: PROTEOMICS, BY COUNTRY, 2021-2029 (USD MILLION)
  • 7.4 METABOLOMICS
    • 7.4.1 ADVANTAGES OF METABOLOMICS OVER GENOMICS AND PROTEOMICS TO DRIVE MARKET GROWTH
    • TABLE 41 METABOLOMICS, BY REGION, 2021-2029 (USD MILLION)
    • TABLE 42 NORTH AMERICA: METABOLOMICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 43 EUROPE: METABOLOMICS, BY COUNTRY, 2021-2029 (USD MILLION)
    • TABLE 44 ASIA PACIFIC: METABOLOMICS, BY COUNTRY, 2021-2029 (USD MILLION)

8 HUMAN MICROBIOME MARKET, BY TYPE

  • 8.1 INTRODUCTION
    • TABLE 45 HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • 8.2 MICROBIOME CONSORTIA TRANSPLANTATION (FMT)
    • 8.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR C. DIFFICILE INFECTION TREATMENT TO AUGMENT SEGMENTAL GROWTH
    • TABLE 46 HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY REGION, 2023-2029 (USD MILLION)
    • TABLE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 2023-2029 (USD MILLION)
    • TABLE 48 EUROPE: HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 2023-2029 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 2023-2029 (USD MILLION)
  • 8.3 PEPTIDE
    • 8.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO GROW IN FORECAST PERIOD
    • TABLE 50 HUMAN MICROBIOME MARKET FOR PEPTIDE, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 51 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PEPTIDE, BY COUNTRY 2023-2029 (USD MILLION)
    • TABLE 52 EUROPE: HUMAN MICROBIOME MARKET FOR PEPTIDE, BY COUNTRY 2023-2029 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PEPTIDE, BY COUNTRY 2023-2029 (USD MILLION)
  • 8.4 LIVE BIOTHERAPEUTIC PRODUCT
    • 8.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST SEGMENTAL GROWTH
    • TABLE 54 HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 55 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 2023-2029 (USD MILLION)
    • TABLE 56 EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 2023-2029 (USD MILLION)
    • TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 2023-2029 (USD MILLION)
  • 8.5 OTHERS
    • 8.5.1 INCREASING FOCUS ON SMALL MOLECULES TO PROPEL SEGMENTAL GROWTH
    • TABLE 58 HUMAN MICROBIOME MARKET FOR OTHERS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 59 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHERS, BY COUNTRY 2023-2029 (USD MILLION)
    • TABLE 60 EUROPE: HUMAN MICROBIOME MARKET FOR OTHERS, BY COUNTRY 2023-2029 (USD MILLION)
    • TABLE 61 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHERS, BY COUNTRY 2023-2029 (USD MILLION)

9 HUMAN MICROBIOME MARKET, BY PRODUCT

  • 9.1 INTRODUCTION
    • TABLE 62 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
  • 9.2 DRUGS
    • 9.2.1 INCREASING NUMBER OF MICROBIOME-BASED DRUGS IN PIPELINE TO DRIVE SEGMENT GROWTH
    • TABLE 63 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 64 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 65 EUROPE: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 66 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 9.3 DIAGNOSTIC TESTS
    • 9.3.1 GROWING CONSUMER AWARENESS ABOUT MICROBIOME- BASED TESTS TO DRIVE SEGMENT GROWTH
    • TABLE 67 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 69 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 9.4 PROBIOTICS
    • 9.4.1 ONGOING RESEARCH PROMOTING CREDIBILITY REGARDING HEALTH CLAIMS AND SAFETY OF PROBIOTICS
    • TABLE 71 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 72 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 73 EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 74 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 9.5 PREBIOTICS
    • 9.5.1 DEVELOPMENT OF TARGETED PREBIOTICS IN ENHANCING GUT MICROBIOTA TO DRIVE SEGMENT GROWTH
    • TABLE 75 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 76 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 77 EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 78 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 9.6 OTHER PRODUCTS
    • TABLE 79 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 80 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 81 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)

10 HUMAN MICROBIOME MARKET, BY DISEASE

  • 10.1 INTRODUCTION
    • TABLE 83 HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
  • 10.2 INFECTIOUS DISEASES
    • 10.2.1 INCREASING NUMBER OF CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO DRIVE SEGMENT GROWTH
    • TABLE 84 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
    • TABLE 85 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 86 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 87 EUROPE: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 88 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 10.3 GASTROINTESTINAL DISEASES
    • 10.3.1 INCREASING NUMBER OF CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO DRIVE SEGMENT GROWTH
    • TABLE 89 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 90 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 91 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 92 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 10.4 ENDOCRINE & METABOLIC DISORDERS
    • 10.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO DRIVE SEGMENT GROWTH
    • TABLE 93 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR METABOLIC DISEASES
    • TABLE 94 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 95 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 96 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 97 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 10.5 CANCER
    • 10.5.1 MICROBIOME-BASED PRODUCTS HAVE DEMONSTRATED EFFICACY IN TREATMENT OF PELVIC AND COLON CANCER
    • TABLE 98 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 99 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 100 EUROPE: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 101 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023-2029 (USD MILLION)
  • 10.6 OTHER DISEASES
    • TABLE 102 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 103 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 104 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)

11 HUMAN MICROBIOME MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 106 HUMAN MICROBIOME MARKET, BY REGION, 2023-2029 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 16 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
    • TABLE 107 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 108 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 109 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 110 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 Increasing investments by NIH in support of microbiome research to drive market growth
    • TABLE 111 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 112 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 113 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Increasing government support and funds to support market growth
    • TABLE 114 INDICATIVE LIST OF PROJECTS ON HUMAN MICROBIOME IN 2018
    • TABLE 115 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 116 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 117 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
  • 11.3 EUROPE
    • FIGURE 17 EUROPE: HUMAN MICROBIOME MARKET SNAPSHOT
    • TABLE 118 EU MICROBIOME PROJECT
    • TABLE 119 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 120 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 121 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 122 EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Extended applications of microbiome research to therapeutic areas to boost adoption of microbiome-based products
    • TABLE 123 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 124 GERMANY: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 125 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • 11.3.2 UK
      • 11.3.2.1 Increasing focus on microbiome-based products development to drive market growth
    • TABLE 126 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 127 UK: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 128 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • 11.3.3 FRANCE
      • 11.3.3.1 Increasing funding to boost microbiome-based products development
    • TABLE 129 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 130 FRANCE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 131 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • 11.3.4 ROE
    • TABLE 132 ROE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 133 ROE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 134 ROE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • FIGURE 18 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
    • TABLE 135 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 136 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 Large number of human microbiome research studies to drive market growth
    • TABLE 139 INDICATIVE LIST OF HUMAN MICROBIOME RESEARCH STUDIES CONDUCTED IN CHINA
    • TABLE 140 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 141 CHINA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 142 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Increasing focus on funding for microbiome-based products to drive market growth
    • TABLE 143 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 144 JAPAN: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 145 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Government funding to drive microbiome-based products development
    • TABLE 146 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 147 INDIA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 148 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • 11.4.4 REST OF ASIA PACIFIC
    • TABLE 149 ROAPAC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 150 ROAPAC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 151 ROAPAC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
  • 11.5 REST OF THE WORLD (ROW)
    • TABLE 152 ROW: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 153 ROW: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 154 ROW: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 PRODUCT TYPE FOOTPRINT OF COMPANIES
    • TABLE 155 PRODUCT TYPE PORTFOLIO ANALYSIS: HUMAN MICROBIOME MARKET (2021)
  • 12.3 CLINICAL PHASE FOOTPRINT OF COMPANIES
    • TABLE 156 CLINICAL PHASE FOOTPRINT OF COMPANIES: HUMAN MICROBIOME MARKET (2021)
  • 12.4 DISEASE FOOTPRINT OF COMPANIES
    • TABLE 157 DISEASE FOOTPRINT OF COMPANIES: HUMAN MICROBIOME MARKET (2021)
  • 12.5 COMPETITIVE SCENARIO
    • TABLE 158 HUMAN MICROBIOME MARKET: KEY DEALS, JANUARY 2020-JANUARY 2021

13 COMPANY PROFILES

  • 13.1 MAJOR PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 13.1.1 ENTEROME
    • TABLE 159 ENTEROME: BUSINESS OVERVIEW
    • 13.1.2 SERES THERAPEUTICS
    • TABLE 160 SERES THERAPEUTICS: BUSINESS OVERVIEW
    • FIGURE 19 SERES THERAPEUTICS: COMPANY SNAPSHOT (2021)
    • 13.1.3 4D PHARMA PLC
    • TABLE 161 4D PHARMA PLC: BUSINESS OVERVIEW
    • FIGURE 20 4D PHARMA PLC: COMPANY SNAPSHOT (2020)
    • 13.1.4 INTERNATIONAL FLAVORS & FRAGRANCES INC.
    • TABLE 162 INTERNATIONAL FLAVORS & FRAGRANCES INC.: BUSINESS OVERVIEW
    • FIGURE 21 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2021)
    • 13.1.5 OPTIBIOTIX HEALTH PLC.
    • TABLE 163 OPTIBIOTIX HEALTH PLC.: BUSINESS OVERVIEW
    • FIGURE 22 OPTIBIOTIX HEALTH PLC.: COMPANY SNAPSHOT (2020)
    • TABLE 164 PRODUCT LAUNCHES
    • 13.1.6 SYNLOGIC, INC.
    • TABLE 165 SYNLOGIC: BUSINESS OVERVIEW
    • FIGURE 23 SYNLOGIC, INC.: COMPANY SNAPSHOT (2020)
    • 13.1.7 SECOND GENOME INC.
    • TABLE 166 SECOND GENOME INC.: BUSINESS OVERVIEW
    • 13.1.8 VEDANTA BIOSCIENCES, INC.
    • TABLE 167 VEDANTA BIOSCIENCES, INC.: BUSINESS OVERVIEW
    • 13.1.9 FERRING PHARMACEUTICALS
    • TABLE 168 FERRING PHARMACEUTICALS: BUSINESS OVERVIEW
    • 13.1.10 EVELO BIOSCIENCES, INC.
    • TABLE 169 EVELO BIOSCIENCES: BUSINESS OVERVIEW
    • FIGURE 24 EVEL0 BIOSCIENCES, INC.: COMPANY SNAPSHOT (2020)
    • 13.1.11 BIOMX
    • TABLE 170 BIOMX: BUSINESS OVERVIEW
    • FIGURE 25 BIOMX: COMPANY SNAPSHOT (2020)
    • 13.1.12 YSOPIA BIOSCIENCE
    • TABLE 171 YSOPIA BIOSCIENCE: BUSINESS OVERVIEW
    • 13.1.13 KALEIDO BIOSCIENCES, INC.
    • TABLE 172 KALEIDO BIOSCIENCES, INC.: BUSINESS OVERVIEW
    • FIGURE 26 KALEIDO BIOSCIENCES, INC.: COMPANY SNAPSHOT (2020)
    • 13.1.14 FLIGHTPATH BIOSCIENCES, INC.
    • TABLE 173 FLIGHTPATH BIOSCIENCES, INC.: BUSINESS OVERVIEW
    • 13.1.15 FINCH THERAPEUTICS GROUP, INC.
    • TABLE 174 FINCH THERAPEUTICS GROUP, INC.: BUSINESS OVERVIEW
    • FIGURE 27 FINCH THERAPEUTICS GROUP, INC.: COMPANY SNAPSHOT (2020)
    • 13.1.16 QUANTBIOME, INC. (DBA OMBRE)
    • TABLE 175 QUANTBIOME, INC.: BUSINESS OVERVIEW
    • 13.1.17 VIOME LIFE SCIENCES, INC.
    • TABLE 176 VIOME LIFE SCIENCES, INC.: BUSINESS OVERVIEW
    • 13.1.18 BIOHM HEALTH
    • TABLE 177 BIOHM HEALTH: BUSINESS OVERVIEW
  • 13.2 OTHER COMPANIES
    • 13.2.1 DAYTWO
    • TABLE 178 DAYTWO: COMPANY OVERVIEW
    • 13.2.2 ATLAS BIOMED
    • TABLE 179 ATLAS BIOMED: COMPANY OVERVIEW
    • 13.2.3 BIONE
    • TABLE 180 BIONE: COMPANY OVERVIEW
    • 13.2.4 LUXIA SCIENTIFIC
    • TABLE 181 LUXIA SCIENTIFIC: COMPANY OVERVIEW
    • 13.2.5 METABIOMICS
    • TABLE 182 METABIOMICS: COMPANY OVERVIEW
    • 13.2.6 SUN GENOMICS
    • TABLE 183 SUN GENOMICS: COMPANY OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 AVAILABLE CUSTOMIZATIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS